Geron Q2 2026 earnings: RYTELO revenue grows as inventory costs weigh on margins

Geron (Nasdaq: GERN) reported Q2 2026 total revenue of $57.48 million, up 17.2% from $49.04 million a year earlier, while diluted net loss per share remained $0.02. RYTELO net product revenue reached $57.47 million, but non-cash inventory-related expenses raised cost of goods sold and kept the quarterly net loss at $16.68 million.

Key earnings data

Nearly all revenue for the quarter ended June 30, 2026 came from RYTELO, with royalty revenue contributing only $7,000. Although product revenue increased, the corresponding rise in cost of goods sold left gross profit nearly unchanged from the prior-year period.

Gross profit and gross margin are approximate calculations based on total revenue less reported cost of goods sold.

RYTELO commercialization and pipeline progress

RYTELO net product revenue increased 11% from Q1 2026, while demand grew 5% sequentially. The number of ordering accounts rose approximately 8% during the quarter to about 1,575, indicating that the product continued to expand its commercial reach in the United States. Management described Q2 as the third consecutive quarter of demand growth.

Geron estimates that the U.S. market includes approximately 8,000 second-line patients with lower-risk myelodysplastic syndromes, or LR-MDS. Its near-term commercial strategy remains focused on reaching more eligible U.S. patients while pursuing access in additional countries.

The company also presented a real-world study of RYTELO in heavily pretreated LR-MDS patients. Geron said the reported efficacy, safety and tolerability were generally consistent with the Phase 3 IMerge trial, though the earnings release did not provide detailed numerical outcomes. Geron continues to advance the Phase 3 IMpactMF trial in relapsed or refractory myelofibrosis.

Inventory-related costs absorbed most of the revenue gain

Total revenue increased by approximately $8.44 million year over year, but cost of goods sold rose by about $8.05 million. As a result, calculated gross profit increased by only about $0.39 million, and gross margin fell from approximately 97.6% to 83.9%.

Geron attributed the higher cost of goods sold primarily to non-cash inventory-related expenses. Total costs and operating expenses consequently increased to $69.98 million from $61.49 million, leaving the operating loss nearly unchanged despite the higher revenue base.

Other operating expenses were comparatively stable. Research and development expense increased to $22.03 million from $21.74 million as manufacturing investments were partly offset by lower headcount costs following the December 2025 workforce reduction. Selling, general and administrative expense rose to $38.86 million from $38.56 million as continued RYTELO commercialization spending was balanced by lower personnel-related administrative costs.

Liquidity and balance sheet

Geron ended June with approximately $326.9 million in cash, cash equivalents, restricted cash and marketable securities, down $14.1 million, or about 4.1%, from March 31, 2026. The company reported total assets of $519.0 million, current liabilities of $70.3 million and noncurrent liabilities of $230.1 million at quarter-end.

Based on its current plans, Geron believes these resources, together with anticipated net revenue from U.S. RYTELO sales, will fund projected operating requirements for the foreseeable future. That assessment depends in part on future product revenue and the company’s spending assumptions.

2026 guidance

Geron reiterated rather than changed its full-year outlook. The company continues to expect RYTELO net product revenue of $220 million to $240 million and total operating expenses of $230 million to $240 million.

First-half RYTELO net product revenue was $109.24 million. Geron therefore needs approximately $110.76 million to $130.76 million in second-half product revenue to finish within its guidance range. The lower end is close to the first-half pace, while reaching the upper end would require a higher second-half revenue total.

Recent insider transactions

The supplied transaction records show two director stock awards and one CFO sale during 2026. These transactions should be viewed objectively and do not by themselves establish insiders’ expectations for the business.

Risks investors should monitor

• Dependence on RYTELO: RYTELO generated virtually all quarterly revenue, making Geron’s results highly dependent on broader adoption within the eligible LR-MDS population.
• Inventory-related margin pressure: Non-cash inventory expenses consumed most of the year-over-year revenue increase. Continued charges could limit improvement in gross profit and operating results.
• Second-half guidance execution: Reaching the upper end of the revenue outlook requires a higher second-half product revenue total than Geron generated during the first six months.
• Cash runway assumptions: The company’s funding assessment relies partly on anticipated U.S. RYTELO revenue and current spending plans. Lower sales or additional investment could change that outlook.
• Clinical and geographic execution: Longer-term expansion depends on progress in the Phase 3 IMpactMF trial and Geron’s ability to establish commercial access outside the United States.

Summary

Geron’s Q2 2026 results showed continued RYTELO adoption, with higher demand, more ordering accounts and double-digit product revenue growth. However, non-cash inventory-related expenses absorbed most of the additional revenue, leaving gross profit and the operating loss nearly unchanged. The main issues to monitor are whether RYTELO demand can support the reiterated full-year guidance, whether inventory costs normalize, and how the company balances commercialization and clinical investment against its available liquidity.